A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
Launched by HOFFMANN-LA ROCHE · Jan 15, 2010
Trial Information
Current as of June 17, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-75 years of age
- • type 2 diabetes mellitus, treated with stable dose of metformin and sulfonylurea for \>/= 12 weeks prior to screening
- • HbA1c 7-10% at screening
- • body weight stable (+/-5%) for \>/= 12 weeks prior to screening
- • fasting C-peptide \>/=1ng/ml
- • treatment-naïve for insulin
- Exclusion Criteria:
- • diagnosis or history of type 1 diabetes mellitus or secondary forms of diabetes
- • acute metabolic diabetic complications or evidence of clinically significant diabetic complications
- • clinically symptomatic gastrointestinal disease
- • history of chronic pancreatitis or acute idiopathic pancreatitis
- • \>3 episodes of severe hypoglycemia within 6 months prior to screening
- • miocardial infarcion, unstable angina pectoris, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within 6 months prior to screening
- • any treatment with exenatide, exendin analogues, GLP-1 or its analogues
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Hong Kong, , Hong Kong
Chengdu, , China
Chongqing, , China
Hangzhou, , China
Seoul, , Korea, Republic Of
Bangkok, , Thailand
Beijing, , China
Chiang Mai, , Thailand
Selangor, , Malaysia
Incheon, , Korea, Republic Of
Manila, , Philippines
Taichung, , Taiwan
Guangzhou, , China
Kelantan, , Malaysia
Putrajaya, , Malaysia
Cebu, , Philippines
Tainan, , Taiwan
Taipei, , Taiwan
Nanjing, Jiangsu, China
Hefei, , China
Taoyuan County, , Taiwan
Busan, , Korea, Republic Of
Kuala Lumpur, , Malaysia
Iloilo, , Philippines
Penang, , Malaysia
Beijng, , China
Nanning, , China
Shi Jiazhuang, , China
Tianjin (天津), , China
Tianjin, , China
Daegu, , Korea, Republic Of
Gyeonggi Do, , Korea, Republic Of
Kangwon Do, , Korea, Republic Of
Kyounggi Do, , Korea, Republic Of
Johor Bahru, , Malaysia
Pasig, , Philippines
Chia Yi City, , Taiwan
Nakhonratchasima, , Thailand
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials